Salt Lake City, Utah — November 5, 2025 — Leads & Copy — Recursion (NASDAQ: RXRX) has announced a leadership transition plan, effective January 1, 2026. Chief R&D and Commercial Officer Najat Khan, Ph.D., will succeed Co-Founder and CEO Chris Gibson, Ph.D., as Chief Executive Officer and President. Gibson will become Chairman of the Board of Directors and an interim Executive Advisor. Current Chairman Rob Hershberg, MD/Ph.D., will transition to Vice-Chairman and Lead Independent Director.
According to Dr. Rob Hershberg, the transition ensures continuity of Recursion’s mission and vision, retaining Gibson’s expertise in the TechBio space. Dr. Gibson stated that after partnering with Khan for 18 months, he has absolute faith that she is the right leader for Recursion’s next phase. Dr. Khan states that Recursion has built something differentiated: a platform that unites biology, chemistry, and AI at unprecedented scale; a pipeline with meaningful near-term readouts; and a culture defined by curiosity, courage, and conviction.
Dr. Khan, who joined Recursion in 2024, has prioritized clinical programs and helped lead the company’s combination with Exscientia. Prior to Recursion, she was Chief Data Science Officer and Senior Vice President at Johnson & Johnson Innovative Medicine. Dr. Khan holds a Ph.D. in Organic Chemistry from the University of Pennsylvania, an AI/ML Certification from MIT’s Computer Science and Artificial Intelligence Laboratory (CSAIL), and a B.A. in Computational Chemistry from Colgate University.
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company decoding biology to radically improve lives. Learn more at www.recursion.com, or connect on X and LinkedIn.
Contact: Ryan Kelly, Recursion Pharmaceuticals, 610-442-1896, ryan.kelly@recursionpharma.com
